Article Information
History
- March 5, 2021.
Article Versions
- Version 1 (December 16, 2020 - 02:03).
- You are currently viewing Version 2 of this article (March 5, 2021 - 14:42).
- Version 3 (May 25, 2021 - 22:54).
- View Version 4, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Douglas F. Lake1,*,#,
- Alexa J. Roeder1,*,
- Erin Kaleta2,
- Paniz Jasbi3,
- Sivakumar Periasamy4,5,
- Natalia Kuzmina4,5,
- Alexander Bukreyev4,5,6,
- Thomas Grys2,
- Liang Wu7,
- John R Mills7,
- Kathrine McAulay2,
- Maria Gonzalez-Moa8,
- Alim Seit-Nebi8 and
- Sergei Svarovsky8
- 1School of Life Sciences, Arizona State University, Tempe AZ, USA
- 2Mayo Clinic Arizona, Department of Laboratory Medicine and Pathology, Scottsdale, AZ, USA
- 3College of Health Solutions, Arizona State University, Phoenix AZ, USA
- 4Department of Pathology, University of Texas Medical Branch at Galveston, Galveston, TX USA
- 5Galveston National Laboratory, University of Texas Medical Branch at Galveston, Galveston, TX USA
- 6Department of Microbiology and Immunology University of Texas Medical Branch at Galveston, Galveston, TX USA
- 7Mayo Clinic Rochester, Department of Laboratory Medicine and Pathology, Rochester, MN USA
- 8Axim Biotechnologies Inc, San Diego, CA USA
- ↵#Address correspondence to Douglas F. Lake, douglas.lake{at}asu.edu
Douglas F Lake and Alexa J Roeder contributed equally to this work. Author order was determined on the basis of seniority
Posted March 05, 2021.
Development of a Rapid Point-Of-Care Test that Measures Neutralizing Antibodies to SARS-CoV-2
